£20.0M
The oversubscribed round included backing from Molten Ventures, Morningside, DCVC, Cambridge Consultants, Civilization Ventures and Providence.
"This substantial investment round demonstrates continued confidence in the progress of our technical development and its potential to revolutionise the accessibility of gene synthesis. Evonetix is in a very exciting phase, having recently opened our early access program. This investment will support us as we execute on our commercial strategy to put benchtop gene synthesis in the hands of users."
E
Evonetix—Cambridge, UKForesite Capital + 6 others
